


**IN THE CLAIMS (37 CFR 1.121 Revised)**

1. (presently amended) An acid addition salt of sertraline:



wherein said salt is selected from the group consisting of the p-toluenesulfonic acid salt, the fumaric acid salt, the benzenesulfonic acid salt, the benzoic acid salt, and the L-tartaric acid salt [and the (-)-camphor-10-sulfonic acid salt].

2. (original) The salt according to claim 1 wherein the salt is the p-toluenesulfonic acid salt.
3. (presently amended) The salt according to claim 2 having an x-ray diffraction pattern characterized [substantially] by an x-ray diffraction pattern peak expressed in terms of an angle  $2\theta$  of 16.6 degrees  $\pm$  0.2 degrees as measured with copper radiation.
4. (presently amended) The salt according to claim 2 having an x-ray diffraction pattern characterized [substantially] by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of  $2\theta$  degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2 $\theta$ ( $\pm$ 0.2)	d-value ( $\text{\AA}$ ) ( $\pm$ 0.2)
6.5	13.6
16.1	5.5
16.6	5.3
20.0	4.4
23.7	4.4
24.0	3.7
25.8	3.5
28.5	3.1

5. (original) The salt according to claim 2 characterized in having an onset of melting transition at about 260 °C.
6. (original) The salt according to claim 1 wherein the salt is the fumaric acid salt.
7. (presently amended) The salt according to claim 6 having an x-ray diffraction pattern characterized [substantially] by an x-ray diffraction pattern peak expressed in terms of an angle 2 $\theta$  of 15.5 degrees  $\pm$  0.2 degrees as measured with copper radiation.
8. (presently amended) The salt according to claim 6 having an x-ray diffraction pattern characterized [substantially] by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2 $\theta$  degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2 $\theta$ ( $\pm$ 0.2)	d-value ( $\text{\AA}$ ) ( $\pm$ 0.2)
13.9	6.4
15.5	5.7
18.3	4.8
19.1	4.6
20.8	4.3
23.0	3.9
23.4	3.8
27.4	3.2

- 
9. (original) The salt according to claim 6 characterized in having an onset of melting transition at about 187 °C.
10. (original) The salt according to claim 1 wherein the salt is the benzenesulfonic acid salt.
- 11-12. (cancelled)
13. (original) The salt according to claim 10 characterized in having a solid-solid transition at about 185 °C and an onset of melting transition at about 230 °C.
14. (original) The salt according to claim 1 wherein the salt is the benzoic acid salt.
15. (presently amended) The salt according to claim 14 having an x-ray diffraction pattern characterized [substantially] by an x-ray diffraction pattern peak expressed in terms of an angle 2 $\theta$  of 16.1 degrees  $\pm$  0.2 degrees as measured with copper radiation.
16. (presently amended) The salt according to claim 14 having an x-ray diffraction pattern characterized [substantially] by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2 $\theta$  degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2 $\theta$ ( $\pm$ 0.2)	d-value ( $\text{\AA}$ ) ( $\pm$ 0.2)
14.9	5.9
16.1	5.5
18.0	4.9
18.5	4.9
19.3	4.6
23.6	4.4
25.0	3.6
25.2	3.5

17. (original) The salt according to claim 14 characterized in having an onset of melting transition at about 154 °C.
18. (original) The salt according to claim 1 wherein the salt is the L-tartaric acid salt.
19. (presently amended) The salt according to claim 18 having an x-ray diffraction pattern characterized [substantially] by an x-ray diffraction pattern peak expressed in terms of an angle 2 $\theta$  of 15.0 degrees  $\pm$  0.2 degrees as measured with copper radiation.
20. (presently amended) The salt according to claim 18 having an x-ray diffraction pattern characterized [substantially] by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2 $\theta$  degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2 $\theta$ ( $\pm$ 0.2)	d-value ( $\text{\AA}$ ) ( $\pm$ 0.2)
13.7	6.5
15.0	5.9
16.7	5.3
18.4	4.8
20.5	4.3
22.1	4.0
22.9	3.9
24.5	3.6

21. (original) The salt according to claim 22 characterized in having an onset of melting transition at about 184 °C.

22-25. (cancelled)

26. (original) A pharmaceutical composition comprising a salt according to claim 1 and a pharmaceutically acceptable carrier or excipient.

27. (original) A method of treating in a mammal a disease, disorder or condition selected from the group consisting of aggression disorders; anxiety disorders, panic attack, agoraphobia, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder and acute stress disorder; cognitive disorders selected from the group consisting of amnesic disorders, amnesic disorders due to a general medical condition, substance-induced persisting amnesic disorder and amnesic disorders not otherwise specified, deliriums, deliriums due to a general medical condition, substance-induced delirium and delirium not otherwise specified, dementias, dementia of the Alzheimer's type, vascular dementia, dementia due to a general medical condition; AIDS-, Parkinson's-, head trauma-, and Huntington's-induced dementias; substance-induced persisting dementia, dementia due to multiple etiologies; depression disorders; emesis; epilepsy; food-related behavioral disorders, anorexia nervosa, bulimia; headache disorders, migraine; cluster and vascular headaches; learning disorders, attention deficit

disorder, attention deficit/hyperactivity disorder; obesity; ocular disorders; platelet aggregation disorders; psychotic conditions, schizophrenia, paranoid-type schizophrenia, disorganized-type schizophrenia, catatonic-type schizophrenia, undifferentiated-type schizophrenia, residual-type schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorders due to a general medical condition; sleep disorders, primary sleep disorders, parasomnias, dyssomnias, sleep disorders related to another mood and anxiety disorders, sleep disorders due to a general medical condition; sexual behavior disorders; substance-abuse disorders, alcohol-related disorders; alcohol-use disorders selected from dependence and abuse disorders; alcohol-induced disorders selected from intoxication, withdrawal, intoxication delirium, withdrawal delirium, persisting dementia, persisting amnesic, mood, anxiety, sexual dysfunction, and sleep disorders; amphetamine-related disorders; amphetamine-use disorders selected from dependence and abuse disorders; amphetamine-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, anxiety, sexual dysfunction and sleep disorders; caffeine-related disorders selected from as intoxication, induced-anxiety disorder, induced-sleep disorder; cannabis-related disorders, cannabis-use disorders selected from abuse and dependence disorders; cannabis-induced disorders selected from intoxication, intoxication delirium, psychotic disorder, and anxiety disorders; cocaine-related disorders; cocaine-use disorders selected from dependence and abuse disorders; cocaine-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, anxiety, sexual dysfunction, sleep disorder; hallucinogen-related disorders, hallucinogen-use disorders selected from dependence and abuse disorders; hallucinogen-induced disorders selected from intoxication, persisting perception, intoxication delirium, psychotic, mood, and anxiety disorder; inhalant-related disorders, inhalant-use disorders selected from dependence and abuse disorders; inhalant-induced disorders selected from intoxication, intoxication delirium, persisting dementia, psychotic, mood, and anxiety disorder; nicotine-related disorders selected from dependence and withdrawal; opioid-related disorders, opioid-use disorders selected from dependence and abuse disorders; opioid-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, sexual dysfunction, and sleep

disorder; phencyclidine-related disorders, phencyclidine-use disorders selected from dependence and abuse disorder; phencyclidine-induced disorders selected from intoxication, intoxication delirium, psychotic, mood, and anxiety disorder; sedative-, hypnotic- or anxiolytic-related disorders, sedative-use disorders selected from dependence and abuse disorders; sedative-induced disorders selected from intoxication, withdrawal, intoxication delirium, withdrawal delirium, persisting dementia, persisting amnestic, psychotic, mood, anxiety, sexual dysfunction, and sleep disorders; polysubstance-related disorder, vision disorders, and glaucoma; comprising administering to a subject in need thereof a therapeutically effective amount of a salt according to claim 1.